Taxus Cardium Pharmaceuticals Group, Inc. (OTCQB: CRXM), formerly Cardium Therapeutics, is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics, including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of patients with cardiac microvascular insufficiency with myocardial ischemia due to advanced coronary artery disease; and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. For more information, visit the company’s website at www.cardiumthx.com